Tian-Xiang Zhang

Tian-Xiang Zhang

Auto-generated profile, based on publicly available information

Tian-Xiang Zhang

Department of Neurology Tianjin Medical University General Hospital Tianjin 300052 China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2021 in Therapeutic Advances in Neurological Disorders
Verified
Journal Article
Open access
PDF file
TZTian-Xiang Zhang
Tian-Xiang Zhang
JCJing-Shan Chen
Jing-Shan Chen
CDChen Du
Chen Du
PZPei Zeng
Pei Zeng
HZHuiming Zhang
Huiming Zhang
CZChao Zhang
Chao Zhang
Neurofilament light chain (NfL) and glial fibrilliary acidic protein (GFAP) have been suggested to be biomarkers of the pathophysiological process of neuromyelitis optica spectrum disorders (NMOSD), but the relationship between the plasma levels of these molecules with disease activity and treatment is incompletely understood. To investigate the treatment effects of disease-modifying drugs on plasma neurofilament light chain (pNfL) and plasma glial fibrillary acidic protein (pGFAP) and explore the predictive value of pNfL and pGFAP in the activity of NMOSD. pNfL and pGFAP levels were measured using single-molecule arrays in 72 patients with NMOSD and 38 healthy controls (HCs). Patients with NMOSD received tocilizumab (n = 29), rituximab (n = 23), oral prednisone (n = 16), and oral azathioprine or mycophenolate mofetil (n = 4). NMOSD patients had significantly higher pNfL and pGFAP levels than HCs (pNfL, 18.3 (11.2–39.3) versus 11.5 (7.0–23.3) pg/mL; p = 0.001; pGFAP, 149.7 (88.6–406.5) versus 68.7 (59.4–80.8) pg/mL; p < 0.001). Multivariable regression analyses indicated that baseline pNfL concentration was associated with age (p = 0.017), Expanded Disability Status Scale (EDSS) score (p = 0.002), and recent relapses (p < 0.001). Baseline pGFAP concentration was also associated with EDSS (p < 0.001) and recent relapses (p < 0.001). Compared with prednisone, tocilizumab and rituximab significantly reduced pNfL [tocilizumab, exp(β), 0.65; 95% confidence interval (CI), 0.56–0.75; p < 0.001; rituximab, exp(β), 0.79; 95% CI = 0.68–0.93; p = 0.005] and pGFAP levels [tocilizumab, exp(β), 0.64; 95% CI, 0.51–0.80; p < 0.001; rituximab, exp(β), 0.77; 95% CI, 0.61–0.98; p = 0.041] at the end of the study. The pNfL levels in the tocilizumab and rituximab groups were reduced to those of HCs [tocilizumab, 8.5 (7.06–17.90) pg/mL; p = 0.426; rituximab, 14.0 (9.94–21.80) pg/mL; p = 0.216]. However, the pGFAP levels did not decrease to those of HCs in NMOSD patients at the end of study [tocilizumab, 88.9 (63.4–131.8) pg/mL; p = 0.012; rituximab, 141.7 (90.8–192.7) pg/mL; p < 0.001]. pNfL and pGFAP may serve as biomarkers for NMOSD disease activity and treatment effects.

29 July 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
Ye LiuYe Liu
Ye Liu
HZHuiming Zhang
Huiming Zhang
TZTian-Xiang Zhang
Tian-Xiang Zhang
MYMeng Yuan
Meng Yuan
CDChen Du
Chen Du
CZChao Zhang
Chao Zhang
Tocilizumab, a humanized anti-IL-6 receptor monoclonal antibody, showed its therapeutic efficacy on neuromyelitis optica spectrum disorder (NMOSD). To assess the immunological effects of this drug on B cells, follicular T helper (Tfh) cells, and peripheral T helper (Tph) cells in patients with NMOSD, peripheral B cell and Tfh cell phenotypes were evaluated in 26 patients with NMOSD before and after tocilizumab treatment by nine-color flow cytometry, as well as the expression of costimulatory and co-inhibitory molecules on B cells. Results showed that the frequency of CD27+IgD− switched memory B cells, CD27-IgD- double-negative B cells, and CD27highCD38high antibody-secreting cells was increased in patients with NMOSD. Tocilizumab treatment led to a significant shift of B cells to naïve B cells from memory B cells after 3 months. Three markers on B cells associated with T-cell activation (i.e., CD86 CD69, and HLA-DR) were downregulated after tocilizumab treatment. The frequencies of total Tfh and Tph cells were decreased, whereas that of follicular regulatory T cells tended to increase. Intrinsic increased PD-L1 and PD-L2 expression was characteristic of B cells in patients with NMOSD. Tocilizumab selectively restored PD-L1 on B-cell subsets. These results provided evidence that tocilizumab enhanced B- and T-cell homoeostasis by regulating B-cell differentiation and inhibiting lymphocyte activation in patients with NMOSD.

1 July 2016 in Animal Reproduction Science
Verified
Journal Article
Closed access
YWYihua Wang
Yihua Wang
SLShuqiang Liu
Shuqiang Liu
SYShuang Yang
Shuang Yang
TZTian-Xiang Zhang
Tian-Xiang Zhang
YWYuting Wei
Yuting Wei
LLLinhai Li
Linhai Li

31 March 2025 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
SYShu Yang
Shu Yang
TZTian‐Xiang Zhang
Tian‐Xiang Zhang
JLJia Liu
Jia Liu
ZLZhirui Liu
Zhirui Liu
LZLijie Zhu
Lijie Zhu
CZChao Zhang
Chao Zhang
Background and Objectives: Ofatumumab, a fully human anti‐CD20 monoclonal antibody, is effective in reducing relapses and disability progression in patients with multiple sclerosis. This study aimed to examine immune profile changes associated with ofatumumab in a prospective cohort of Chinese patients with relapsing–remitting multiple sclerosis (RRMS).Methods: Seventeen RRMS patients were enrolled in this uncontrolled, prospective, observational cohort study (OMNISCIENCE study) and received regular subcutaneous ofatumumab treatments. Immune cell subsets were analyzed by single‐cell mass cytometry at baseline and 6 months post‐treatment. Peripheral blood monoclonal cells (PBMCs) from a separate cohort of treatment‐naive RRMS patients were used for cytokine analysis through ex vivo flow cytometry.Results: Following ofatumumab treatment, B cells in peripheral blood remained depleted, with surviving cells predominantly consisting of antibody‐secreting cells and transitional B cells. Increased proportions of NK cells and myeloid cells, particularly HLA‐DRhi intermediate monocytes, were observed, and FOXP3 and CTLA‐4 expression on CD4+ T cells was upregulated. Notably, prior to the subsequent dose of ofatumumab, Th17.1‐like CXCR3+CCR6+ memory CD4+ and CD8+ T cell clusters increased significantly, with a transient CD20 expression rebound. In vitro experiments further confirmed that ofatumumab reduced these Th17.1 cell subsets and related pro‐inflammatory cytokines.Discussion: These findings suggest that ofatumumab impacts interactions among pathogenic B cells, T cells, and myeloid cells, with Th17.1 cells emerging as a potential direct target within T cells. Persistent and regular infusions of ofatumumab appear necessary to sustain clinical efficacy.Trial Registration: ClinicalTrials.gov identifier: NCT05414487

21 July 2025 in Advanced Science
Verified
Journal Article
Open access
TZTian‐Xiang Zhang
Tian‐Xiang Zhang
XYXiaoxiao Yang
Xiaoxiao Yang
XGXue Gao
Xue Gao
XDXiaoshan Du
Xiaoshan Du
XLXuegan Lian
Xuegan Lian
CZChao Zhang
Chao Zhang
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease characterized by anti‐aquaporin 4 (AQP4) antibody‐mediated astrocyte damage and subsequent demyelination. Prior attempts to treat NMOSD with interferon‐beta (IFN‐β), a disease‐modifying therapy for multiple sclerosis, resulted in worsening of disease activity, with an unknown mechanism. Here, robust activation of the cGAS‐STING‐IFN‐I signaling pathway is identified in myeloid cells in both the periphery and central nervous system. The abnormal IFN‐I response gives rise to an increase in the number of AQP4 antigen‐specific autoreactive T cells. Sting deficiency can significantly blunt the activation of AQP4‐specific T cells, as well as the IFN‐I activity in microglia, and attenuate astrocyte damage. Consequently, the clinical manifestation of NMOSD is ameliorated in a passive transfer mouse model of NMOSD. Further, treatment with STING inhibitor H151 alleviates the severity of NMOSD mouse models. These findings uncover the cGAS‐STING‐IFN‐I pathway in promoting autoreactive T cells and establish a foundation for inhibiting this pathway as a new therapeutic revenue for NMOSD.

6 June 2025 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
SWSi-Ting Wu
Si-Ting Wu
TZTian-Xiang Zhang
Tian-Xiang Zhang
ZLZhirui Liu
Zhirui Liu
XAXueting An
Xueting An
XDXiaoshan Du
Xiaoshan Du
CZChao Zhang
Chao Zhang
Never in mitosis gene A (NIMA)-related kinase 2 (NEK2), a member of the serine-threonine kinase family, is critically involved in the regulation of the cell cycle. Upregulation of NEK2 is associated with aberrant B cell proliferation, a phenomenon potentially driven by NEK2-mediated disruption of the PKM1/PKM2 equilibrium. The overexpression of NEK2 in the B cell lineage may facilitate the maturation processes of B cells. Nonetheless, the precise role of NEK2 in modulating B cell-mediated immunity in autoimmune disorders remains to be fully elucidated. In this study, we demonstrate that NEK2 was significantly upregulated in multiple sclerosis (MS) patients. Pharmacological inhibition of NEK2 resulted in a marked reduction in the expression of co-stimulatory molecules CD80 and CD86 on B cells, concomitant with a suppression of their proliferation and differentiation into antibody-secreting cells (ASCs) and class-switched memory B cells (SWM). Administration of the NEK2 inhibitor INH1 in a murine model of experimental autoimmune encephalomyelitis (EAE) led to notable improvements in neurological function, amelioration of demyelination, and a decrease in the infiltration of inflammatory cells in the central nervous system (CNS) compared to vehicle-treated EAE mice. Mass cytometry analysis revealed that NEK2 inhibition downregulated the expression of co-stimulatory molecules and diminished the proportion of Th1 cells in the CD4 + T cell population. In vitro studies further substantiated that NEK2 blockade attenuated CD4 + T cell proliferation and differentiation into Th1 cells by disrupting B-T cell interactions. Collectively, these findings underscore an immunomodulatory function for NEK2 and highlight its potential as a therapeutic target in the treatment of multiple sclerosis.